By leveraging reference compounds with comparable pharmacological profiles, a PBPK model is constructed to extrapolate human pharmacokinetics from preclinical animal data. The model predicts minimum effective doses and maximum tolerated doses to define a suitable dose range for First-in-Human clinical trials.